301201 logo

ChengDa Pharmaceuticals XSEC:301201 Stock Report

Last Price

CN¥20.87

Market Cap

CN¥3.2b

7D

-4.3%

1Y

-17.5%

Updated

26 Dec, 2024

Data

Company Financials

ChengDa Pharmaceuticals Co., Ltd.

XSEC:301201 Stock Report

Market Cap: CN¥3.2b

301201 Stock Overview

Engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. More details

301201 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends2/6

My Notes

Capture your thoughts, links and company narrative

ChengDa Pharmaceuticals Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for ChengDa Pharmaceuticals
Historical stock prices
Current Share PriceCN¥20.87
52 Week HighCN¥26.72
52 Week LowCN¥14.60
Beta0.28
1 Month Change-3.78%
3 Month Change8.13%
1 Year Change-17.51%
3 Year Changen/a
5 Year Changen/a
Change since IPO-28.76%

Recent News & Updates

Recent updates

Shareholder Returns

301201CN PharmaceuticalsCN Market
7D-4.3%-2.3%-0.5%
1Y-17.5%-5.4%9.2%

Return vs Industry: 301201 underperformed the CN Pharmaceuticals industry which returned -4.3% over the past year.

Return vs Market: 301201 underperformed the CN Market which returned 10.8% over the past year.

Price Volatility

Is 301201's price volatile compared to industry and market?
301201 volatility
301201 Average Weekly Movement9.2%
Pharmaceuticals Industry Average Movement7.4%
Market Average Movement8.8%
10% most volatile stocks in CN Market13.0%
10% least volatile stocks in CN Market5.7%

Stable Share Price: 301201 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 301201's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1980557Gang Luwww.chengdapharm.com

ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. It offers APIs; bulk drugs for urogenital, musculoskeletal system, and antineoplastic and immunomodulators; and drug intermediates for blood and hematopoietic organs, digestive tract and metabolism, and nervous system. The company was founded in 1980 and is based in Jiaxing, China.

ChengDa Pharmaceuticals Co., Ltd. Fundamentals Summary

How do ChengDa Pharmaceuticals's earnings and revenue compare to its market cap?
301201 fundamental statistics
Market capCN¥3.16b
Earnings (TTM)CN¥70.19m
Revenue (TTM)CN¥397.81m

45.0x

P/E Ratio

7.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
301201 income statement (TTM)
RevenueCN¥397.81m
Cost of RevenueCN¥223.85m
Gross ProfitCN¥173.96m
Other ExpensesCN¥103.77m
EarningsCN¥70.19m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.46
Gross Margin43.73%
Net Profit Margin17.64%
Debt/Equity Ratio0%

How did 301201 perform over the long term?

See historical performance and comparison

Dividends

1.0%

Current Dividend Yield

44%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 07:30
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ChengDa Pharmaceuticals Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution